52 results on '"Koschmieder, Steffen"'
Search Results
2. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells
3. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
4. Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis
5. Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry
6. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
7. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
8. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
9. Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
10. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
11. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
12. Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
13. Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
14. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
15. Essenzielle Thrombozythämie und Polycythaemia vera
16. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
17. Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms
18. Towards personalized medicine with iPS cell technology: a case report of advanced systemic mastocytosis with associated eosinophilia
19. 61/w mit Blutungen und Thrombose bei Thrombozytose: Vorbereitung auf die Facharztprüfung: Fall 32
20. Second versus first wave of COVID-19 in patients with MPN
21. Breakthrough infections in MPN-COVID vaccinated patients
22. Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells
23. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
24. Inflammatory Responses of Astrocytes Are Independent from Lipocalin 2
25. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
26. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
27. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
28. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
29. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms
30. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms
31. Dexamethasone nanomedicines for COVID-19
32. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
33. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
34. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
35. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
36. Biobankinganforderungen aus Sicht des Klinikers: Erfahrungen aus der Hämatologie und Onkologie
37. Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway
38. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita
39. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
40. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
41. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
42. Hematopoietic stem and progenitor cell proliferation and differentiation requires the trithorax protein Ash2l
43. Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
44. Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
45. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
46. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians
47. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)
48. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)
49. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia
50. POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.